Scholar Rock (NASDAQ:SRRK) Given Buy Rating at HC Wainwright

Scholar Rock (NASDAQ:SRRK - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $30.00 price objective on the stock. HC Wainwright's target price indicates a potential upside of 106.90% from the stock's current price.

A number of other equities research analysts have also recently commented on SRRK. Raymond James started coverage on Scholar Rock in a research report on Thursday, March 28th. They set a "strong-buy" rating and a $30.00 target price on the stock. Truist Financial restated a "buy" rating and issued a $20.00 price objective on shares of Scholar Rock in a research report on Wednesday, April 3rd. Wedbush reaffirmed an "outperform" rating and set a $23.00 target price on shares of Scholar Rock in a research note on Tuesday. Finally, Piper Sandler reissued an "overweight" rating and issued a $28.00 price target on shares of Scholar Rock in a research note on Tuesday, March 26th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $25.17.

Scholar Rock Stock Performance

NASDAQ:SRRK traded down $0.19 during trading hours on Wednesday, reaching $14.50. The company had a trading volume of 614,211 shares, compared to its average volume of 767,036. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.80 and a quick ratio of 8.80. Scholar Rock has a 1-year low of $5.56 and a 1-year high of $21.17. The business's 50 day moving average price is $15.20 and its 200-day moving average price is $14.95. The firm has a market cap of $1.16 billion, a PE ratio of -7.37 and a beta of 0.94.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.11). During the same quarter in the previous year, the business posted ($0.46) EPS. Research analysts forecast that Scholar Rock will post -2.01 EPS for the current year.

Insider Transactions at Scholar Rock

In other Scholar Rock news, General Counsel Junlin Ho sold 3,489 shares of the business's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.74, for a total transaction of $54,916.86. Following the transaction, the general counsel now owns 208,771 shares of the company's stock, valued at $3,286,055.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Mo Qatanani sold 2,512 shares of the company's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.74, for a total value of $39,538.88. Following the transaction, the insider now directly owns 147,019 shares in the company, valued at $2,314,079.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Junlin Ho sold 3,489 shares of the firm's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.74, for a total value of $54,916.86. Following the sale, the general counsel now directly owns 208,771 shares of the company's stock, valued at approximately $3,286,055.54. The disclosure for this sale can be found here. Insiders have sold a total of 22,359 shares of company stock worth $351,931 in the last ninety days. Insiders own 26.20% of the company's stock.

Hedge Funds Weigh In On Scholar Rock

A number of hedge funds have recently modified their holdings of SRRK. Amalgamated Bank boosted its stake in Scholar Rock by 52.8% during the third quarter. Amalgamated Bank now owns 4,217 shares of the company's stock worth $30,000 after buying an additional 1,458 shares during the period. Silverarc Capital Management LLC acquired a new stake in Scholar Rock in the 3rd quarter valued at approximately $69,000. State Board of Administration of Florida Retirement System purchased a new stake in Scholar Rock in the third quarter valued at approximately $88,000. SG Americas Securities LLC acquired a new position in Scholar Rock during the third quarter worth $153,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Scholar Rock by 479.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,346 shares of the company's stock worth $157,000 after buying an additional 6,905 shares during the period. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.